

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.**  
**( 深圳市海普瑞藥業集團股份有限公司 )**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock code: 9989)**

**INSIDE INFORMATION**

**(1) DELAY IN PUBLICATION OF AUDITED ANNUAL RESULTS  
ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2021;  
(2) PUBLICATION OF UNAUDITED ANNUAL RESULTS  
ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2021;  
AND  
(3) DATE OF BOARD MEETING**

This announcement is made by Shenzhen Hepalink Pharmaceutical Group Co., Ltd (the “**Company**”, together with its subsidiaries as the “**Group**”) pursuant to the Inside Information Provisions (as defined in the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Listing Rules.

## **DELAY IN PUBLICATION OF AUDITED ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2021**

The board (the “**Board**”) of directors (the “**Directors**”) of the Company would like to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that the Group’s auditing process for the year ended 31 December 2021 (“**FY2021**”) has been adversely affected due to the implementation of the COVID-19 pandemic prevention and control quarantine measures in certain cities (including Shenzhen and Shanghai) in mainland China, including delay in receiving audit confirmations due to delays in postal services, and suspension of work and closure of some offices of the Group in the PRC due to lockdown measures in mainland China which affected the preparation and gathering process of necessary documents and information required for the audit work. Given that the auditor of the Company (the “**Auditor**”) requires additional time for conducting its audit work, it is anticipated that the Company will be unable to publish the audited consolidated annual results of the Group (the “**2021 Audited Annual Results**”) for FY2021 on or before 31 March 2022 in accordance with Rules 13.49(1) and 13.49(2) of the Listing Rules. The Company expects to publish the 2021 Audited Annual Results upon completion of such reporting and audit processes after the 2021 Audited Annual Results have been finalised and agreed by the Auditor as soon as practicable, on or before 12 April 2022. Further announcement(s) will be made by the Company as and when appropriate.

## **PUBLICATION OF UNAUDITED ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2021**

Rule 13.49(3) of the Listing Rules provides that where an issuer is unable to issue its preliminary results not later than three months after the end of the financial year according to Rules 13.49(1) and 13.49(2) of the Listing Rules, it must announce its results based on the financial results which have yet to be agreed with the Auditor (so far as the information is available). In order to keep the Shareholders and potential investors informed of the Group’s business operation and financial position, the Company expects to publish the unaudited consolidated annual results of the Group for the FY2021 (the “**2021 Unaudited Annual Results**”), which will have been reviewed by the audit committee of the Company but have not been agreed with the Auditor, together with the audited comparable figures for the corresponding period in 2020 on 30 March 2022.

The aforesaid delay in publication of the 2021 Audited Annual Results will constitute the Company’s non-compliances with Rules 13.49(1) and 13.49(2) of the Listing Rules. Notwithstanding the aforesaid, the Board wishes to emphasise that the operation of the Group remains normal and the Company will continue to work with its Auditor closely to publish the 2021 Audited Annual Results.

## **DATE OF BOARD MEETING**

Reference is made to the announcement of the Company dated 18 March 2022, the Board meeting will continue to be held on Wednesday, 30 March 2022, but the purposes of the meeting will be changed to, among other matters, approving the announcement of the 2021 Unaudited Annual Results and considering the payment of a final dividend, if any.

The Company will make further announcement(s) in accordance with Rule 13.43 of the Listing Rules as and when appropriate.

**Shareholders and potential investors should exercise caution when dealing in shares of the Company.**

By order of the Board  
**Shenzhen Hepalink Pharmaceutical Group Co., Ltd.**  
**Li Li**  
*Chairman*

Hong Kong, 29 March 2022

*As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Bin; and the independent non-executive*